Abstract | PURPOSE: This study analyzed the effect of adalimumab on peripheral blood mononuclear cells (PBMCs) in uveitis. METHODS: PBMCs and serum S100A12 levels from 14 uveitis patients and 28 healthy controls were analyzed. Patient samples were taken before (w0), and 6 (w6) and 12 ( w12) weeks after initiation of adalimumab therapy. RESULTS: Monocytes expressing CD124, CD86, CD39, CD115, and MHCII were decreased in patients. Adalimumab induced CD86+ and CD39+ monocytes, and further decreased the frequency of MHCII- and CD124-positive cells. Patients (w0) had increased percentages of Th1-, Th17-, and Th2 cells and T cell subsets showed a pro-inflammatory polarization (p = 0.02 ratio Th17/Treg patients w0 vs controls), which was reduced upon adalimumab treatment (p = 0.05 w0 vs w6). S100A12 levels were increased in patients (p = 0.02) and reduced under treatment (p = 0.02 for w6/ w12). CONCLUSIONS: The phenotype of PBMCs from uveitis patients is modified upon adalimumab treatment. Serum S100A12 levels reflect the systemic immune response.
|
Authors | Karoline Walscheid, Toni Weinhage, Dirk Foell, Carsten Heinz, Maren Kasper, Arnd Heiligenhaus |
Journal | Ocular immunology and inflammation
(Ocul Immunol Inflamm)
Vol. 27
Issue 2
Pg. 330-337
( 2019)
ISSN: 1744-5078 [Electronic] England |
PMID | 29020495
(Publication Type: Journal Article)
|
Chemical References |
- Anti-Inflammatory Agents
- Adalimumab
|
Topics |
- Adalimumab
(administration & dosage)
- Adolescent
- Anti-Inflammatory Agents
(administration & dosage)
- Child
- Child, Preschool
- Dose-Response Relationship, Drug
- Female
- Humans
- Leukocytes, Mononuclear
(drug effects, immunology, pathology)
- Male
- Monocytes
(drug effects, immunology, pathology)
- Retrospective Studies
- T-Lymphocytes, Regulatory
(drug effects, immunology, pathology)
- Treatment Outcome
- Uveitis
(blood, drug therapy, immunology)
|